Company Filing History:
Years Active: 2011-2019
Title: Innovations by Inventor Stephane Pintat in Pharmaceutical Chemistry
Introduction
Stephane Pintat, based in Abingdon, GB, is an accomplished inventor with a notable portfolio of three patents. His work primarily focuses on pharmaceutical innovations, particularly in the field of kinase inhibitors, which have significant implications for medical treatments.
Latest Patents
Among his latest patents, Pintat has developed 2-aminopyrazine derivatives that serve as CSF-1R kinase inhibitors. This invention includes a compound formula that offers a variety of therapeutic options. The compounds are particularly beneficial in medical applications due to their ability to inhibit CSF-1R kinase. Another groundbreaking patent from Pintat involves inhibitors of P38 MAP kinase. This invention provides a range of compounds that are useful in treating autoimmune and inflammatory diseases, showcasing his commitment to addressing complex medical challenges.
Career Highlights
Currently, Stephane Pintat is associated with Chroma Therapeutics Limited, where he contributes to innovative research and development in drug discovery. His scientific acumen and innovative mindset have enabled him to develop compounds that are not only novel but also have practical applications in medicine.
Collaborations
Stephane has had the opportunity to collaborate with notable colleagues such as Stephen John Davies and David Festus Charles Moffat. These collaborations highlight the importance of teamwork in driving scientific advancements and achieving successful outcomes in complex projects.
Conclusion
In summary, Stephane Pintat is a distinguished inventor whose contributions to pharmaceutical chemistry have the potential to create impactful medical solutions. His latest innovations as CSF-1R kinase and P38 MAP kinase inhibitors reflect his dedication to improving health through scientific discovery and innovation.